首頁 > 市場調查報告書 > 製藥

生物製劑

市場調查報告書

商品編碼

1746846

日本人體微生物組市場報告（按產品、應用、疾病類型和地區）2025-2033

Japan Human Microbiome Market Report by Product, Application, Disease Type, and Region 2025-2033

出版日期: 2025年06月02日 | 出版商:

IMARC | 英文 115 Pages | 商品交期: 5-7個工作天內

價格

簡介目錄

2024年，日本人體微生物組市場規模達2,140萬美元。展望未來， IMARC Group預計到2033年，該市場規模將達到1.675億美元，2025-2033年期間的複合年成長率（CAGR）為23.70%。生命科學和生物技術領域的許多進步，以及政府機構在升級整體生物技術基礎設施方面不斷增加的投資，是推動市場成長的主要動力。

人類微生物組涵蓋了存在於人類集體基因組成（稱為宏基因組）中的各種微生物的遺傳物質。它包含多種微生物，包括細菌、真菌、原生動物、非生物病毒和各種單細胞生物。這些微生物對人體生理產生影響，並在增強或損害代謝和免疫功能方面發揮作用。它們分佈在人體組織的各個角落，是醫學和分析方法進步的研究對象。微生物組在益生菌、益生元、藥物以及針對各種疾病（包括但不限於糖尿病、肥胖、癌症以及與代謝、胃腸系統、神經系統（中樞和外周）和自體免疫疾病相關的疾病）的診斷和治療系統等領域都有應用。

日本人體微生物組市場趨勢：

在日本市場，該產業的成長受到多個關鍵因素的推動。一個重要促進因素是慢性生活方式相關疾病和微生物失衡導致的感染發病率不斷上升，這一趨勢在全球範圍內普遍存在。此外，日本老齡人口的成長也促進了市場擴張，老年人更容易受到此類健康狀況的影響。此外，市場的成長也歸功於對開發更有效的人體微生物組療法的高度重視。例如，研究人員正在配製特定的人體腸道微生物組組合，以更有效地治療各種胃腸道疾病。新冠疫情的爆發也刺激了市場成長，因為正在進行廣泛的研究，以檢查肺部微生物組、評估感染嚴重程度以及開發合適的治療方法和疫苗。此外，諸如針對特定目標的微生物組療法的開發等進步正在促進市場擴張。其他推動因素包括強勁的研發活動和製藥業的顯著成長，尤其是在發展中經濟體，所有這些都有望在未來幾年推動市場向前發展。

日本人類微生物組市場細分：

產品洞察：

益生菌
益生元
診斷測試
藥物
醫療食品
其他

應用程式洞察：

療法
診斷

疾病類型洞察：

肥胖
糖尿病
自體免疫疾病
癌症
胃腸道疾病
中樞神經系統疾病
其他

競爭格局：

市場研究報告也對競爭格局進行了全面的分析。報告涵蓋了市場結構、關鍵參與者定位、最佳制勝策略、競爭儀錶板和公司評估象限等競爭分析。此外，報告還提供了所有主要公司的詳細資料。

本報告回答的關鍵問題：

日本人體微生物組市場迄今表現如何？未來幾年將如何表現？
COVID-19 對日本人體微生物組市場有何影響？
日本人體微生物組市場依產品分類是怎樣的？
日本人體微生物組市場根據應用如何分佈？
根據疾病類型，日本人體微生物組市場是如何分類的？
日本人類微生物組市場的價值鏈分為哪些階段？
日本人體微生物組的主要促進因素和挑戰是什麼？
日本人類微生物組市場的結構是怎麼樣的？主要參與者是誰？
日本人體微生物組市場的競爭程度如何？

本報告回答的關鍵問題：

日本人體微生物組市場迄今表現如何？未來幾年將如何表現？
COVID-19 對日本人體微生物組市場有何影響？
日本人體微生物組市場依產品分類是怎樣的？
日本人體微生物組市場根據應用如何分佈？
根據疾病類型，日本人體微生物組市場是如何分類的？
日本人類微生物組市場的價值鏈分為哪些階段？
日本人體微生物組的主要促進因素和挑戰是什麼？
日本人類微生物組市場的結構是怎麼樣的？主要參與者是誰？
日本人體微生物組市場的競爭程度如何？

Japan human microbiome market size reached USD 21.4 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 167.5 Million by 2033, exhibiting a growth rate (CAGR) of 23.70% during 2025-2033. Numerous advancements in the field of life science and biotechnology, along with the rising investments by government bodies in upgrading the overall biotechnology infrastructures, are primarily driving the market growth.

The human microbiome encompasses the genetic material present within a diverse array of microorganisms contained in the collective genetic makeup, known as the metagenome, of humans. It comprises a multitude of microorganisms, including bacteria, fungi, protozoans, non-living viruses, and various single-celled organisms. These microorganisms exert an influence on human physiology and play a role in either enhancing or compromising metabolic and immune functions. They are distributed throughout human tissues and are subjects of study for advancements in medicine and analytical methodologies. Microbiomes find applications in areas such as probiotics, prebiotics, pharmaceutical drugs, and diagnostic and therapeutic systems tailored to address various medical conditions, including but not limited to diabetes, obesity, cancer, as well as disorders related to metabolism, the gastrointestinal system, the nervous system (both central and peripheral), and autoimmune diseases.

Japan Human Microbiome Market Trends:

In the Japanese market context, the growth of the industry is being propelled by several key factors. One significant driver is the increasing incidence of chronic lifestyle-related diseases and infections resulting from microbial imbalances, a trend observed worldwide. Additionally, the growing elderly population in Japan, which is more susceptible to such health conditions, is contributing to market expansion. Furthermore, the market's growth is attributed to the heightened focus on developing human microbiome therapies with enhanced effectiveness. For instance, researchers are formulating specific combinations of human gut microbiomes to treat various gastrointestinal disorders more effectively. The outbreak of the COVID-19 pandemic has also spurred market growth, as extensive research is underway to examine lung microbiomes, assess infection severity, and develop suitable therapeutics and vaccines. Moreover, advancements like the creation of microbiome-based therapies tailored to specific targets are fostering market expansion. Other contributing factors include robust research and development (R&D) activities and significant growth in the pharmaceutical sector, particularly in developing economies, all of which are poised to propel the market forward in the coming years.

Japan Human Microbiome Market Segmentation:

Product Insights:

Probiotics
Prebiotics
Diagnostic Tests
Drugs
Medical Food
Others

Application Insights:

Therapeutics
Diagnostics

Disease Type Insights:

Obesity
Diabetes
Autoimmune Disorders
Cancer
Gastrointestinal Disorders
Central Nervous System Disorders
Others

Competitive Landscape:

The market research report has also provided a comprehensive analysis of the competitive landscape. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.

Key Questions Answered in This Report:

How has the Japan human microbiome market performed so far and how will it perform in the coming years?
What has been the impact of COVID-19 on the Japan human microbiome market?
What is the breakup of the Japan human microbiome market on the basis of product?
What is the breakup of the Japan human microbiome market on the basis of application?
What is the breakup of the Japan human microbiome market on the basis of disease type?
What are the various stages in the value chain of the Japan human microbiome market?
What are the key driving factors and challenges in the Japan human microbiome?
What is the structure of the Japan human microbiome market and who are the key players?
What is the degree of competition in the Japan human microbiome market?

1 Preface

2 Scope and Methodology

2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Japan Human Microbiome Market - Introduction

4.1 Overview
4.2 Market Dynamics
4.3 Industry Trends
4.4 Competitive Intelligence

5 Japan Human Microbiome Market Landscape

5.1 Historical and Current Market Trends (2019-2024)
5.2 Market Forecast (2025-2033)

6 Japan Human Microbiome Market - Breakup by Product

6.1 Probiotics
- 6.1.1 Overview
- 6.1.2 Historical and Current Market Trends (2019-2024)
- 6.1.3 Market Forecast (2025-2033)
6.2 Prebiotics
- 6.2.1 Overview
- 6.2.2 Historical and Current Market Trends (2019-2024)
- 6.2.3 Market Forecast (2025-2033)
6.3 Diagnostic Tests
- 6.3.1 Overview
- 6.3.2 Historical and Current Market Trends (2019-2024)
- 6.3.3 Market Forecast (2025-2033)
6.4 Drugs
- 6.4.1 Overview
- 6.4.2 Historical and Current Market Trends (2019-2024)
- 6.4.3 Market Forecast (2025-2033)
6.5 Medical Food
- 6.5.1 Overview
- 6.5.2 Historical and Current Market Trends (2019-2024)
- 6.5.3 Market Forecast (2025-2033)
6.6 Others
- 6.6.1 Historical and Current Market Trends (2019-2024)
- 6.6.2 Market Forecast (2025-2033)

7 Japan Human Microbiome Market - Breakup by Application

7.1 Therapeutics
- 7.1.1 Overview
- 7.1.2 Historical and Current Market Trends (2019-2024)
- 7.1.3 Market Forecast (2025-2033)
7.2 Diagnostics
- 7.2.1 Overview
- 7.2.2 Historical and Current Market Trends (2019-2024)
- 7.2.3 Market Forecast (2025-2033)

8 Japan Human Microbiome Market - Breakup by Disease Type

8.1 Obesity
- 8.1.1 Overview
- 8.1.2 Historical and Current Market Trends (2019-2024)
- 8.1.3 Market Forecast (2025-2033)
8.2 Diabetes
- 8.2.1 Overview
- 8.2.2 Historical and Current Market Trends (2019-2024)
- 8.2.3 Market Forecast (2025-2033)
8.3 Autoimmune Disorders
- 8.3.1 Overview
- 8.3.2 Historical and Current Market Trends (2019-2024)
- 8.3.3 Market Forecast (2025-2033)
8.4 Cancer
- 8.4.1 Overview
- 8.4.2 Historical and Current Market Trends (2019-2024)
- 8.4.3 Market Forecast (2025-2033)
8.5 Gastrointestinal Disorders
- 8.5.1 Overview
- 8.5.2 Historical and Current Market Trends (2019-2024)
- 8.5.3 Market Forecast (2025-2033)
8.6 Central Nervous System Disorders
- 8.6.1 Overview
- 8.6.2 Historical and Current Market Trends (2019-2024)
- 8.6.3 Market Forecast (2025-2033)
8.7 Others
- 8.7.1 Historical and Current Market Trends (2019-2024)
- 8.7.2 Market Forecast (2025-2033)

9 Japan Human Microbiome Market - Competitive Landscape

9.1 Overview
9.2 Market Structure
9.3 Market Player Positioning
9.4 Top Winning Strategies
9.5 Competitive Dashboard
9.6 Company Evaluation Quadrant

10 Profiles of Key Players

10.1 Company A
- 10.1.1 Business Overview
- 10.1.2 Product Portfolio
- 10.1.3 Business Strategies
- 10.1.4 SWOT Analysis
- 10.1.5 Major News and Events
10.2 Company B
- 10.2.1 Business Overview
- 10.2.2 Product Portfolio
- 10.2.3 Business Strategies
- 10.2.4 SWOT Analysis
- 10.2.5 Major News and Events
10.3 Company C
- 10.3.1 Business Overview
- 10.3.2 Product Portfolio
- 10.3.3 Business Strategies
- 10.3.4 SWOT Analysis
- 10.3.5 Major News and Events
10.4 Company D
- 10.4.1 Business Overview
- 10.4.2 Product Portfolio
- 10.4.3 Business Strategies
- 10.4.4 SWOT Analysis
- 10.4.5 Major News and Events
10.5 Company E
- 10.5.1 Business Overview
- 10.5.2 Product Portfolio
- 10.5.3 Business Strategies
- 10.5.4 SWOT Analysis
- 10.5.5 Major News and Events

11 Japan Human Microbiome Market - Industry Analysis

11.1 Drivers, Restraints, and Opportunities
- 11.1.1 Overview
- 11.1.2 Drivers
- 11.1.3 Restraints
- 11.1.4 Opportunities
11.2 Porters Five Forces Analysis
- 11.2.1 Overview
- 11.2.2 Bargaining Power of Buyers
- 11.2.3 Bargaining Power of Suppliers
- 11.2.4 Degree of Competition
- 11.2.5 Threat of New Entrants
- 11.2.6 Threat of Substitutes
11.3 Value Chain Analysis